Drugs / MK-3655
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04583423 | Nov 2020 → Apr 2023 | metabolic dysfunction-associated steatohepatitis | Merck Sharp & Dohme LLC | Terminated | Missed primary Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-3655 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04583423 ↗ |
| Action | Activate | “selectively activates the FGFR1c/β-klotho co-receptor complex” PMID 39984821 ↗ Feb 2025 |
| Modality | Monoclonal antibody | “MK-3655, a monoclonal antibody” PMID 39984821 ↗ Feb 2025 |
| Route | Subcutaneous | “Participants were randomised 1:1:1:1 to receive MK-3655 50 mg, 100 mg, 300 mg, or matching placebo subcutaneously every 4 weeks” PMID 39984821 ↗ Feb 2025 |